{"transactions":[{"id":930968,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T07:00:07.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date is January 1, 2026.  The stock option vests in 48 substantially equal monthly installments.  Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter."}],"balance_after":230000,"derivative":{"exercise_price":1.26,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001193125-26-021657","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000119312526021657/ownership.xml","form_type":"4"}},{"id":1296139,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2025-01-23T16:05:10.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025."}],"balance_after":95000,"derivative":{"exercise_price":2.57,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000950170-25-008319","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017025008319/ownership.xml","form_type":"4"}},{"id":1427220,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":48703,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":48703,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":48703},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427219,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":76173,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":76173,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":76173},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427218,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":94871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427217,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":62820,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":62820,"derivative":{"exercise_price":3.56,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":62820},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427216,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":10256,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":10256,"derivative":{"exercise_price":3.56,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":10256},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427215,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":48703},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427214,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76173,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":76173},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427213,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427212,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62820,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":62820},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1427211,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:11:48.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10256,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":3.71,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":10256},"source":{"system":"sec-edgar","filing":"0000950170-24-099308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024099308/ownership.xml","form_type":"4"}},{"id":1557388,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-03-29T16:30:08.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":48703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":48703,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":48703},"source":{"system":"sec-edgar","filing":"0000950170-24-038692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730657/000095017024038692/ownership.xml","form_type":"4"}},{"id":3611568,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-05T17:27:21.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":155000,"derivative":{"exercise_price":1.96,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-19-016738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919119016738/doc4.xml","form_type":"4"}},{"id":4007990,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":68776,"kind":"person","name":"Hassig Christian","position":1,"cik":"0001730657","reported_name":"Hassig Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-07T17:54:34.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":205180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":205180,"derivative":{"exercise_price":2.36,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":205180},"source":{"system":"sec-edgar","filing":"0001209191-18-017778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919118017778/doc4.xml","form_type":"4"}}]}